Sirtris Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
23 May 2007 - 8:00PM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, today announced
the pricing of its initial public offering of 6,000,000 shares of
its common stock at $10.00 per share, before underwriting discounts
and commissions. All of the common stock is being offered by
Sirtris. In addition, Sirtris has granted the underwriters a 30-day
option to purchase up to an additional 900,000 shares to cover
over-allotments, if any. J.P. Morgan Securities Inc. is acting as
the sole book-running manager and CIBC World Markets Corp., Piper
Jaffray & Co., JMP Securities LLC, and Rodman & Renshaw,
LLC are acting as co-managers for the offering. The shares will
trade on the NASDAQ Global Market under the symbol "SIRT." A
registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on May 22nd,
2007. The public offering is being made by means of a written
prospectus. Copies of the final prospectus relating to the offering
may be obtained from: J.P. Morgan Securities Inc., Attention:
Prospectus Department, 4 Chase Metrotech Center, CS Level,
Brooklyn, NY 11245. Phone: (718) 242-8002. Email:
addressing.services@jpmorgan.com. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy,
nor shall there be any sale of these securities in any state in
which such offer, solicitation or sale would be unlawful prior to
their registration or qualification under the securities laws of
any such state. About Sirtris Pharmaceuticals Sirtris
Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small
molecule drugs with the potential to treat diseases associated with
aging, including metabolic diseases such as Type 2 Diabetes. Our
drug candidates are designed to mimic certain beneficial health
effects of calorie restriction, without requiring a change in
eating habits, by activation of sirtuins, a recently discovered
class of enzymes. The company's headquarters are in Cambridge,
Massachusetts.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles